ARTICLE | Clinical News
Alagebrium: Started Phase II
January 24, 2005 8:00 AM UTC
ALT started a double-blind, placebo-controlled, U.S. Phase II EMERALD trial in about 40 diabetic male patients with moderate to severe ED who achieved limited benefit with phosphodiesterase-5 (PDE-5) ...